{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-062722","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.879252+00:00","generated_at":"2026-05-18T17:51:37.137355+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered","bullets":["China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.","Approval triggers $7.5M milestone from Viatris, expected Q3 2025; eligible for up to $37.5M in sales milestones and 14-20% tiered royalties.","Viatris responsible for all development/commercialization; Theravance incurs no commercial costs in China.","Theravance cash $131M (Mar 31), plus $225M from TRELEGY royalty sale and up to $150M near-term TRELEGY milestones.","Theravance nearing completion of enrollment in open-label portion of CYPRESS study of ampreloxetine for nOH in MSA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-062722","json":"https://secwatch.observer/filing/0001104659-25-062722.json","markdown":"https://secwatch.observer/filing/0001104659-25-062722.md","text":"https://secwatch.observer/filing/0001104659-25-062722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/0001104659-25-062722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/tm2519052d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:51:37.137355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}